Innovative approaches to the therapy of fibrosis

Current Opinion in Rheumatology

Volumn 21, Issue 6, 2009, Pages 649-655

  De Andrade, Joao A ^a,b   Thannickal, Victor J ^a  

^a and Clinical Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

3 hydroxymethylglutaryl Coenzyme A reductase inhibitors; Apoptosis; Endothelin receptor antagonists; Epithelial cells; Fibroblasts; Mesenchymal stem cells; Peroxisome proliferator activated receptor gamma agonists; Protein kinase inhibitors

Indexed keywords

ANTIFIBROTIC AGENT; BOSENTAN; FASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INITIATION FACTOR 4E; KERATINOCYTE GROWTH FACTOR; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN KINASE INHIBITOR; ROSIGLITAZONE; SCATTER FACTOR; TROGLITAZONE;

CELL ACTIVATION; CELL REGENERATION; CELL SURVIVAL; CELL THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIUM CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROGENESIS; FIBROSIS; HOMEOSTASIS; HUMAN; LUNG FIBROSIS; MESENCHYME CELL; MYOFIBROBLAST; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SKIN FIBROSIS;

EUKARYOTIC INITIATION FACTOR-4E; FIBROBLAST GROWTH FACTOR 7; FIBROSIS; HEPATOCYTE GROWTH FACTOR; HOMEOSTASIS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; NADPH OXIDASE; NITRIC OXIDE; PHENOTYPE; PPAR GAMMA; PROTEIN KINASE INHIBITORS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

EID: 70349814386     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328330da9b     Document Type: Review

References (80)

1. Thannickal VJ,ToewsGB, White ES, et al. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004; 55:395-417.
2. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666.
3. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161:646-664.
4. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis: ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991; 138:1257-1265.
5. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3:350-356.
6. Lawson WE, Crossno PF, Polosukhin VV, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 2008; 294:L111 9-1126.
7. Korfei M, RuppertC, Mahavadi P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178:838-846.
8. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008; 105:13051-13056.
9. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178:729-737.
10. Thannickal VJ, Loyd JE. Idiopathic pulmonary fibrosis: a disorder of lung regeneration? Am J Respir Crit Care Med 2008; 178:663-665.
11. Horowitz JC, Rogers DS, Sharma V, et al. Combinatorial activation of FAKand AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal 2007; 19:761-771.
12. Jun JB, Kuechle M, Harlan JM, et al. Fibroblast and endothelial apoptosis in systemic sclerosis. Curr Opin Rheumatol 2003; 15:756-760.
13. MimuraY, Ihn H, Jinnin M, et al. Constitutive phosphorylation offocal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol 2005; 124:886-892.
14. Jun JB, Kuechle M, Min J, et al. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J Invest Dermatol 2005; 124:298-303.
15. Adamson IY, Young L, Bowden DH. Relationship of alveolar epithelial injury and repair to the induction of pulmonary fibrosis. Am J Pathol 1988; 130:377-383.
16. Chilosi M, Poletti V, Zamo A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162:1495-1502.
17. Uhal BD. Apoptosis in lung fibrosis and repair. Chest 2002; 122:293S-298S.
18. Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesench-ymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005; 166:1321-1332.
19. Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in-vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006; 103:13180-13185.
20. Shukla MN, Rose JL, Ray R, et al. Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7. Am J Respir Cell Mol Biol 2009; 40:643-653.
21. Mizuno S, Matsumoto K, Li MY, et al. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 2005; 19:580-582.
22. Yaekashiwa M, Nakayama S, Ohnuma K, et al. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin: a morphologic study. Am J Respir Crit Care Med 1997; 156:1937-1944.
23. Dohi M,HasegawaT,Yamamoto K, et al. Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000; 162:2302-2307.
24. Watanabe M, Ebina M, Orson FM, et al. Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. Mol Ther 2005; 12:58-67.
25. Gazdhar A, Fachinger P, van Leer C,et al. Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 292:L529-L536.
26. Marchand-Adam S, Plantier L, Bernuau D, et al. Keratinocyte growth factor expression by fibroblasts in pulmonary fibrosis: poor response to interleukin-1beta. Am J Respir Cell Mol Biol 2005; 32:470-477.
27. Yi ES, Williams ST, Lee H, et al. Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality. Am J Pathol 1996; 149:1963-1970.
28. Deterding RR, Havill AM, Yano T, et al. Prevention of bleomycin-induced lung injury in rats by keratinocyte growth factor. Proc Assoc Am Physicians 1997; 109:254-268.
29. Sugahara K, Iyama K, Kuroda MJ, et al. Double intratracheal instillation of keratinocyte growth factor prevents bleomycin-induced lung fibrosis in rats. J Pathol 1998; 186:90-98.
30. Vyas-Read S, Shaul PW, Yuhanna IS, et al. Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2007; 293:L212-L221.
31. McCurnin DC, Pierce RA, Chang LY, et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2005; 288:L450-L459.
32. Ghosh B, Benyumov AO, Ghosh P, et al. Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol 2009; 4:367-377.
33. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003; 100:8407-8411.
34. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the anti-inflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007; 104:11002-11007.
35. Kotton DN, Fabian AJ, Mulligan RC. Failure of bone marrow to reconstitute lung epithelium. Am J Respir Cell Mol Biol 2005; 33:328-334.
36. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all postnatal organs and tissues. J Cell Sci 2006; 119:2204-2213.
37. Lama VN, Smith L, Badri L, et al. Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. J Clin Invest 2007; 117:989-996.
38. Summer R, Fitzsimmons K, Dwyer D, et al. Isolation of an adult mouse lung mesenchymal progenitor cell population. Am J Respir Cell Mol Biol 2007; 37:152-159.
39. Wang D, Haviland DL, Burns AR, et al. A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2007; 104:4449-4454.
40. Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170:1807-1816.
41. Desmouliere A, Geinoz A, Gabbiani F, et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofi-broblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122:103-111.
42. Thannickal VJ, Lee DY, White ES, et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 2003; 278:12384-12389.
43. Hinz B, Mastrangelo D, Iselin CE, et al. Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. Am J Pathol 2001; 159:1009-1020.
44. Becker J, Delayre-Orthez C, Frossard N, et al. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 2006; 20:429-447.
45. Genovese T, Cuzzocrea S, Di Paola R, et al. Effect of rosiglitazone and 15-deoxy-delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J 2005; 25:225-234.
46. Milam JE, Keshamouni VG, Phan SH, et al. PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294:L891-L901.
47. Wu M, Melichian DS, Chang E, et al. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxi-some proliferator-activated receptor-gamma. Am J Pathol 2009; 174: 519-533.
48. Cohen P. Protein kinases: the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1:309-315.
49. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002; 346:683-693.
50. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002; 8:S14-S18.
51. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-145.
52. Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114:1308-1316.
53. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56:311-322.
54. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60:219-224.
55. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006; 173:769-776.
56. Aono Y, Nishioka Y, Inayama M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005; 171:1279-1285.
57. Vittal R, Zhang H, Han MK, et al. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J Pharmacol Exp Ther 2007; 321:35-44.
58. Vittal R, Horowitz JC, Moore BB, et al. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am J Pathol 2005; 166:367-375.
59. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
60. Shi-Wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15:2707-2719.
61. Park SH, Saleh D, Giaid A, et al. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997; 156:600-608.
62. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177:75-81.
63. King TE Jr. Bosentan for idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2008; 9:1171-1179.
64. Burridge K, Chrzanowska-Wodnicka M. Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol 1996; 12:463-518.
65. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007; 50:17-24.
66. Watts KL, Sampson EM, Schultz GS, et al. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol 2005; 32:290-300.
67. Ou XM, Feng YL, Wen FQ, et al. Simvastatin attenuates bleomycin-induced pulmonary fibrosis in mice. Chin Med J (Engl) 2008; 121:1821-1829.
68. Kinnula VL, Fattman CL, Tan RJ, et al. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005; 172:417-422.
69. Gabrielli A, Svegliati S, Moroncini G, et al. Oxidative stress and the pathogen-esis of scleroderma: the Murrell s hypothesis revisited. Semin Immunopathol 2008; 30:329-337.
70. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000; 279:L1005-L1028.
71. Thannickal VJ. Oxygen in the evolution of complex life and the price we pay. Am J Respir Cell Mol Biol 2009; 40:507-510.
72. Kawahara T, Quinn MT, Lambeth JD. Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes. BMC Evol Biol 2007; 7:109.
73. Bedard K, Lardy B, Krause KH. NOX family NADPH oxidases: not just in mammals. Biochimie 2007; 89:1107-1112.
74. Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J 2008; 275:3249-3277.
75. Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibro-blasts into myofibroblasts. Circ Res 2005; 97:900-907.
76. Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009 (in press).
77. Waghray M, Cui Z, Horowitz JC, et al. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J 2005; 19:854-856.
78. Rhyu DY, Yang Y, Ha H, et al. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesench-ymal transition in renal tubular epithelial cells. J Am Soc Nephrol 2005; 16:667-675.
79. Larios JM, Budhiraja R, Fanburg BL, et al. Oxidative protein cross-linking reactions involving L-tyrosine in transforming growth factor-beta1-stimulated fibroblasts. J Biol Chem 2001; 276:17437-17441.
80. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151.